Continuation of this work may point to CacyBP/SIP as a potent factor able to attenuate α-synuclein pathology and may create basis for development of new therapeutic strategies applicable in treatment of PD and other synucleinopathies. This evidence concerns the gene SNCA and Parkinson disease.